Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- - Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways -
- 03/06/2025
|
Solid Biosciences to Participate at Upcoming Investor Conferences
- CHARLESTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- 03/05/2025
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,950 restricted stock units (“RSUs”) to one newly hired employee.
- 03/04/2025
|
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
- 02/19/2025
|
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
- On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
- 02/18/2025
|
Solid Biosciences Announces Pricing of Underwritten Offering
- CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per pre-funded warrant. The aggregate gross proceeds of the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. All of the securities in the offering are being sold by Solid. The offering is expected to close on or about February 19, 2025, subject to the satisfaction of customary closing conditions.
- 02/18/2025
|
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
- — Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants by Q4 2025 —— In mid-2025, Company plans to request an FDA meeting to discuss potential accelerated approval pathway for SGT-003 —— Company to hold a conference call today at 8:00 AM ET —
- 02/18/2025
|
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
- Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025.
- 01/21/2025
|
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
- - Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation -
- 01/21/2025
|
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
- - Duchenne : Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
- 01/15/2025
|
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
- 01/08/2025
|
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
- Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
- 01/08/2025
|
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia
- - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -
- 01/07/2025
|
Solid Biosciences Added to the Nasdaq Biotechnology Index
- CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
- 12/23/2024
|
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
- Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).
- 12/13/2024
|
Solid Biosciences to Participate at Upcoming Investor Conferences
- CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- 11/26/2024
|
Solid Biosciences to Present at the Jefferies London Healthcare Conference
- CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
- 11/14/2024
|
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
- - Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
- 11/06/2024
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired employees.
- 10/02/2024
|
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
- CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET.
- 09/12/2024
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired employees.
- 09/04/2024
|
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
- – Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
- 08/13/2024
|
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
- 07/01/2024
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired employees.
- 06/04/2024
|
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
- Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
- 05/20/2024
|
SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024
- Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
- 05/15/2024
|
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
- — Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
- 05/15/2024
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired employees.
- 05/02/2024
|
Buy Solid Biosciences: Unpacking Its Main Value Driver
- Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
- 04/10/2024
|
How this insider trader nailed every single stock trade
- Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
- 04/05/2024
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/03/2024
|
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
- Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
- 04/02/2024
|
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
- – SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.
- 04/01/2024
|
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
- Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
- 03/28/2024
|
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
- — Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —
- 03/13/2024
|
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
- The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
- 02/18/2024
|
Another Huge Buffett Purchase Highlights Recent Insider Buying
- The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
- 02/12/2024
|
Joe Lewis, billionaire owner of Tottenham Hotspur football club, pleads guilty to insider trading
- British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.
- 01/24/2024
|
More Big Warren Buffett Purchases Highlight Recent Insider Buying
- The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.
- 01/20/2024
|
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
- Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
- 01/17/2024
|
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
- IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.
- 01/16/2024
|
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
- – Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.
- 01/16/2024
|
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
- The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
- 01/15/2024
|
Solid Biosciences Announces $109 Million Private Placement
- CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).
- 01/08/2024
|
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
- Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
- 12/08/2023
|
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
- Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
- 11/16/2023
|
Are Gene Therapy Stocks The Market's Next Big Winners?
- It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘
- 09/25/2023
|
Solid Biosciences to Present at JMP Securities Life Sciences Conference
- CHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 1:00 PM ET.
- 05/08/2023
|
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
- CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 8:00 AM ET.
- 04/13/2023
|
Solid Biosciences to Present at Barclays Global Healthcare Conference
- CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 3:35 PM ET.
- 03/07/2023
|
Solid Biosciences to Present at SVB Securities Global Biopharma Conference
- CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 1:40 pm ET.
- 02/08/2023
|
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 am PT / 12:00 pm ET.
- 01/09/2023
|
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
- Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
7 Sizzling Stocks That Are Oblivious to the Manic Market
- It's a scientific reality that people don't operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out of their positions, the dynamic presents discounted opportunities for battle-hardened contrarians.
- 10/20/2022
|
Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results - Earnings Call Transcript
- Solid Biosciences Inc. (NASDAQ:SLDB ) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ET Company Participants Caitlin Lowie - VP, Communications and IR Ilan Ganot - Co-Founder, President and CEO Dr. Joel Schneider - COO Dr. Carl Morris - Chief Scientific Officer Dr. Roxana Donisa Dreghici - SVP and Head, Clinical Development Conference Call Participants Gena Wang - Barclays Joseph Schwartz - SVB Securities Allison Bratzel - Piper Sandler Anupam Rama - JP Morgan Maury Raycroft - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Solid Biosciences Strategic Business Update and Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to Caitlin Lowie, Vice President of Communications and Investor Relations at Solid Biosciences.
- 04/30/2022
|
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
- Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/27/2022
|
Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial
- Solid Biosciences Inc (NASDAQ: SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001.
- 03/14/2022
|
Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
- CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 4:20 pm ET.
- 02/10/2022
|
All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy
- Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/05/2022
|
5 Short Squeeze Penny Stocks To Buy For Under $5 Right Now
- 5 short squeeze penny stocks to buy for under $5. Are they worth the risk?
- 11/05/2021
|
2 Net Current Asset Value Stocks to Consider
- There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share prices to near or above the liquidation value.
- 10/29/2021
|
7 Best Penny Stocks to Buy on the Nasdaq for October
- Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.
- 09/29/2021
|
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
- - Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post administration -
- 09/29/2021
|
Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data
- Solid Biosciences Inc (NASDAQ: SLDB) reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 1/2 trial of SGT-001. SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy for Duchenne muscular dystrophy (DMD).
- 09/23/2021
|
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
- - Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) -
- 09/23/2021
|
Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options
- Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
- 09/22/2021
|
SLDB Stock: Why It Significantly Increased Today
- The stock price of Solid Biosciences Inc (NASDAQ: SLDB) increased by over 14% during intraday trading today. This is why it happened.
- 09/21/2021
|
Why Shares of Solid Biosciences Are Jumping Today
- Shareholders are expecting to finally get good news.
- 09/21/2021
|
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
- - Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress -
- 09/20/2021
|
Solid Biosciences to Participate at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event and Chardan's 5th Annual Genetic Medicines Conference.
- 09/20/2021
|
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021
- - Chief Operating Officer to discuss company's advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development -
- 08/24/2021
|
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
- CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Finance, Michael Inbar. The grant was approved by a majority of the independent directors of the Company on July 27, 2021 as an inducement material to Mr. Inbar entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/19/2021
|
Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates
- Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 5.56% and 14.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/16/2021
|
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results
- - Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 -
- 08/16/2021
|
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
- CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior Vice President, Clinical Development, Roxana Dreghici. The grant was approved by a majority of the independent directors of the Company on June 16, 2021 as an inducement material to Dr. Dreghici entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/02/2021
|
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
- CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer, Dr. Iman Barilero. The grant was approved by a majority of the independent directors of the Company on May 5, 2021 as an inducement material to Dr. Barilero entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/07/2021
|
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
- CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective June 1, 2021.
- 06/07/2021
|
Solid Biosciences to Present at Upcoming Scientific Conferences
- CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific conferences:
- 05/25/2021
|
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q1 2021 Results - Earnings Call Transcript
- Solid Biosciences' (SLDB) CEO Ilan Ganot on Q1 2021 Results - Earnings Call Transcript
- 05/14/2021
|
Solid Biosciences (SLDB) Stock: Over 20% Decrease Explanation
- The stock price of Solid Biosciences Inc (NASDAQ: SLDB) decreased by over 20% during intraday trading. This is why it happened.
- 05/14/2021
|
Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results
- - Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event -
- 05/14/2021
|
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
- CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louise Perry, Head of Technical Operations, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 10:30 am ET.
- 04/20/2021
|
Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
- CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled “The more we learn the less we know about DMD—From micro-dystrophin, to morpholinos, and small molecules” will be held on Thursday, April 1, 2021 from 9:00 a.m. - 9:50 a.m. Eastern Time.
- 03/25/2021
|
Should You Buy Solid Biosciences (SLDB) Ahead of Earnings?
- Solid Biosciences (SLDB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/24/2021
|
Edgewise Therapeutics Proposes Terms For $150 Million IPO
- Edgewise Therapeutics has filed to raise $150 million in an IPO.
- 03/23/2021
|
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
- CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its previously announced underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $5.75 per share, including 3,260,869 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $143.8 million.
- 03/23/2021
|
Solid Biosciences Announces Pricing of Public Offering of Common Stock
- CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Solid has granted the underwriters a 30-day option to purchase up to an additional 3,260,869 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Solid. The offering is expected to close on March 23, 2021, subject to customary closing conditions.
- 03/18/2021
|
Solid Biosciences Announces Proposed Public Offering of Common Stock
- CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has commenced an underwritten public offering of $85 million of shares of its common stock. All of the shares are being offered by Solid. In addition, Solid expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering on the same terms and conditions.
- 03/17/2021
|
Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options
- Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
- 03/17/2021
|
Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down
- Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.
- 03/16/2021
|
Why Solid Biosciences Stock Is Crashing Today
- Investors appear to be skeptical about the biotech's latest clinical update.
- 03/16/2021
|
Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors
- Solid Biosciences Inc (NASDAQ: SLDB) reported interim functional, biomarker data, and patient-reported outcome measures from its ongoing IGNITE Phase 1/2 trial of its lead gene therapy candidate, SGT-001 in Duchenne muscular dystrophy (DMD). While IGNITE-DMD was designed to assess the microdystrophin protein expression and distribution, the company instead chose to highlight the functional and patient-reported outcomes at the 12-month mark.
- 03/16/2021
|
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort
- - Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and clinically validated patient reported outcome measures (PROMs) -
- 03/15/2021
|
Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
- CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Legal Officer, Erin Brennan. The grant was approved by a majority of the independent directors of the Company on February 25, 2021 as an inducement material to Ms. Brennan entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/04/2021
|
Efficacy and Safety Data from Solid Biosciences' Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference
- - IGNITE DMD Principal Investigator, Dr. Barry Byrne, to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18-
- 02/24/2021
|
Solid Biosciences to Present at Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn Clary, MD, MBA, Acting Chief Medical Officer, will participate at the following two upcoming investor conferences:
- 02/17/2021
|
Why Solid Biosciences Stock Is Sinking Today
- Blame it on Sarepta.
- 01/08/2021
|
Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20 am ET. Following the prepared remarks, several members of the leadership team will be available for Q&A.
- 01/06/2021
|
Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life Sciences
- Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction in HbA1c. Tv Therapeutics Inc operates in the United States health care sector.
- 12/11/2020
|
Solid Biosciences Announces $90 Million Private Placement
- CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions.
- 12/11/2020
|
Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
- SLDB is recovering from clinical holds placed on lead drug candidate SGT-001 for DMD. They entered a new deal with Ultragenyx, and have cash for the next year.
- 11/10/2020
|
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript
- Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update
- –IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 –
- 11/05/2020
|
Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020
- CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release third quarter 2020 financial results before the market opens on Thursday, November 5, 2020. Management will host a conference call on the same date beginning at 8:30 a.m. ET to discuss the Company's financial results and recent business developments.
- 11/03/2020
|
